無料セミナー : 2019年11月19日『手術用ロボット:外科医療におけるトランスフォーメーション』 BIS Research共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

リアルワールドエビデンス (RWE) ソリューションの世界市場:コンポーネント別・用途別・エンドユーザー別の将来予測

Real World Evidence Solutions Market by Component, Application, End User - Global Forecast to 2024

発行 Meticulous Market Research Pvt. Ltd. 商品コード 798160
出版日 ページ情報 英文 166 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.13円で換算しております。
Back to Top
リアルワールドエビデンス (RWE) ソリューションの世界市場:コンポーネント別・用途別・エンドユーザー別の将来予測 Real World Evidence Solutions Market by Component, Application, End User - Global Forecast to 2024
出版日: 2019年02月20日 ページ情報: 英文 166 Pages
概要

当レポートでは、世界のリアルワールドエビデンス (RWE) ソリューションの市場について分析し、市場の基本構造や主な促進・抑制要因、全体的な市場動向見通し (過去2年間・今後6年間分)、コンポーネント別・用途別・エンドユーザー別・地域別の詳細動向、近年の市場競争・資本取引の動き、主要企業のプロファイルなどを調査しております。

第1章 イントロダクション

第2章 分析手法

第3章 エグゼクティブ・サマリー

第4章 市場考察

  • イントロダクション
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の課題

第5章 リアルワールドエビデンス (RWE) ソリューション市場:コンポーネント別

  • イントロダクション
  • データセット
    • 個別データセット
      • 電子カルテ (EMR/EHR)、臨床データ
      • 請求・課金データ
      • 薬局データ
      • 製品/疾患レジストリデータ
      • その他
    • 一体型データセット
  • コンサルティング/サービス

第6章 RWEソリューション市場:用途別

  • イントロダクション
  • 薬剤開発 (創薬)・認証:治療領域別
    • 腫瘍
    • 心血管疾患
    • 神経症
    • 免疫疾患
    • その他
  • 市場アクセス、医療費償還/保険補償範囲の決定
  • 臨床意思決定
  • 医療機器の開発・認証
  • その他

第7章 RWEソリューション市場:エンドユーザー別

  • イントロダクション
  • 製薬/バイオテクノロジー/医療機器企業
  • 医療費支払者 (ペイヤー)
  • 医療提供者 (プロバイダー)
  • その他

第8章 RWEソリューション市場:地域別

  • イントロダクション
  • 北米 (米国、カナダ)
  • 欧州 (英国、ドイツ、フランス、イタリア、スペインなど)
  • アジア太平洋地域 (日本、中国など)
  • 他の国々 (RoW)

第9章 競争環境

  • 主な成長戦略
  • 企業間の比較分析

第10章 企業プロファイル

  • Anthem, Inc.
    • 事業概要
    • 主な財務指標
    • 製品ポートフォリオ
    • 戦略展開状況
  • Clinigen Group plc
  • Cognizant Technology Solutions (CTS) Corporation
  • IBM Corporation
  • ICON plc
  • IQVIA
  • Optum (United Health Group, Inc.の子会社)
  • Oracle Corporation
  • PAREXEL International Corporation
  • PerkinElmer Inc.
  • Pharmaceutical Product Development, LLC
  • SAS Institute Inc.
  • Syneos Health, Inc.

第11章 付録

図表

List of Tables

  • Table 1 Global Real-World Evidence Solutions Market: Impact Analysis of Market Drivers (2019-2024)
  • Table 2 Global Real-World Evidence Solutions Market: Impact Analysis of Market Restraint (2019-2024)
  • Table 3 Global RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 4 Global Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 5 Global Data Sets Market Size, by Country/ Region, 2017-2024 ($Million)
  • Table 6 Global Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 7 Global Disparate Data Sets Market Size, by Country/ Region, 2017-2024 ($Million)
  • Table 8 Global EMR/EHR/Clinical Data Sets Market Size For RWE, by Country/ Region, 2017-2024 ($Million)
  • Table 9 Global Claims & Billing Data Market Size For RWE, by Country/ Region, 2017-2024 ($Million)
  • Table 10 Global Pharmacy Data Market Size for RWE, By Country/ Region, 2017-2024 ($Million)
  • Table 11 Global Product/Disease Registries Market Size for RWE, By Country/ Region, 2017-2024 ($Million)
  • Table 12 Global Other Data Market Size For RWE, By Country/ Region, 2017-2024 ($Million)
  • Table 13 Global Integrated Data Sets Market Size For RWE, By Country/ Region, 2017-2024 ($Million)
  • Table 14 Global RWE Services Market Size, By Country/ Region, 2017-2024 ($Million)
  • Table 15 Global Real-World Evidence Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 16 Global RWE Solutions Market Size for Drug Development & Approvals, by Therapeutic Area, 2017-2024 ($ Million)
  • Table 17 Global RWE Solutions Market Size for Drug Development & Approvals, by Country/ Region, 2017-2024 ($Million)
  • Table 18 Global RWE Solutions Market Size for Oncological Drug Development & Approvals, by Country/ Region, 2017-2024 ($Million)
  • Table 19 Global RWE Solutions Market Size for Cardiovascular Drug Development & Approvals, by Country/ Region, 2017-2024 ($Million)
  • Table 20 Number of Drugs in Development for key Neurological Conditions
  • Table 21 Global RWE Solutions Market Size for Neurological Drug Development & Approvals, by Country/ Region, 2017-2024 ($Million)
  • Table 22 R&D Pipeline for Immunological Disorders
  • Table 23 Global RWE Solutions Market Size For Immunological Drug Development & Approvals, By Country/ Region, 2017-2024 ($Million)
  • Table 24 R&D Pipeline for Other Disorders
  • Table 25 Global RWE Solutions Market Size for other Drug Development & Approvals, by Country/ Region, 2017-2024 ($Million)
  • Table 26 Global RWE Solutions Market Size for Market Access & Reimbursement/ Coverage Decisions, by Country/ Region, 2017-2024 ($Million)
  • Table 27 Global RWE Solutions Market Size for Clinical Decision Making, by Country/ Region, 2017-2024 ($Million)
  • Table 28 Global RWE Solutions Market Size for Medical Device Development & Approvals, by Country/ Region, 2017-2024 ($Million)
  • Table 29 Global RWE Solutions Market Size for Other Applications, by Country/ Region, 2017-2024 ($Million)
  • Table 30 Global RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 31 Global RWE Solutions Market Size for Pharmaceutical, Biotechnology & Medical Device Companies, by Country/ Region, 2017-2024 ($Million)
  • Table 32 Global RWE Solutions Market Size for Healthcare Payers, by Country/ Region, 2017-2024 ($Million)
  • Table 33 Global RWE Solutions Market Size for Healthcare Providers, by Country/ Region, 2017-2024 ($Million)
  • Table 34 Global RWE Solutions Market Size for Other End Users, by Country/ Region, 2017-2024 ($Million)
  • Table 35 Global Real-World Evidence Solutions Market Size, by Country, 2017-2024 ($Million)
  • Table 36 North America: RWE Solutions Market Size, by Country, 2017-2024 ($Million)
  • Table 37 North America: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 38 North America: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 39 North America: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 40 North America: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 41 North America: RWE Market Size For Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 42 North America: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 43 U.S.: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 44 U.S.: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 45 U.S.: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 46 U.S.: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 47 U.S.: RWE Market Size for Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 48 U.S.: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 49 Active Clinical Trials in Canada, 2018
  • Table 50 Canada: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 51 Canada: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 52 Canada: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 53 Canada: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 54 Canada: RWE Market Size For Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 55 Canada: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 56 Europe: RWE Solutions Market Size, by Country, 2017-2024 ($Million)
  • Table 57 Europe: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 58 Europe: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 59 Europe: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 60 Europe: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 61 Europe: RWE Solutions Market Size for Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 62 Europe: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 63 Adoption of Wearable Health Devices in U.K., 2015-17
  • Table 64 U.K.: Conferences and Workshops on Real-World Evidence Solutions
  • Table 65 U.K.: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 66 U.K.: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 67 U.K.: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 68 U.K.: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 69 U.K.: RWE Market Size for Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 70 U.K.: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 71 Germany: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 72 Germany: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 73 Germany: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 74 Germany: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 75 Germany: RWE Market Size For Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 76 Germany: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 77 France: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 78 France: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 79 France: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 80 France: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 81 France: RWE Market Size For Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 82 France: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 83 Italy: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 84 Italy: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 85 Italy: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 86 Italy: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 87 Italy: RWE Market Size For Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 88 Italy: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 89 Spain: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 90 Spain: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 91 Spain: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 92 Spain: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 93 Spain: RWE Market Size for Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 94 Spain: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 95 RoE: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 96 RoE: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 97 RoE: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 98 RoE: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 99 RoE: RWE Market Size for Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 100 RoE: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 101 APAC: RWE Solutions Market Size, by Country, 2017-2024 ($Million)
  • Table 102 APAC: RWE Market Size, by Component, 2017-2024 ($Million)
  • Table 103 APAC: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 104 APAC: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 105 APAC: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 106 APAC: RWE Market Size for Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 107 APAC: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 108 Japan: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 109 Japan: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 110 Japan: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 111 Japan: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 112 Japan: RWE Market Size for Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 113 Japan: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 114 China: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 115 China: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 116 China: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 117 China: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 118 China: RWE Market Size for Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 119 China: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 120 Real-World Evidence Related Conferences Held in RoAPAC Region, 2017-18
  • Table 121 RoAPAC: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 122 RoAPAC: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 123 RoAPAC: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 124 RoAPAC: RWE Solutions Market, by Application, 2017-2024 ($Million)
  • Table 125 RoAPAC: RWE Market Size For Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 126 RoAPAC: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 127 RoW: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 128 RoW: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 129 RoW: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 130 RoW: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 131 RoW: RWE Market Size For Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 132 RoW: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 133 Number Of Developments Made by The Profiled Companies, January 2015-January 2019
  • Table 134 Key Products: Real-World Evidence Solutions

List of Figures

  • Figure 1 Market Ecosystem
  • Figure 2 Key Stakeholders of Real-World Evidence Solutions Market
  • Figure 3 Research Process
  • Figure 4 Key Executives Interviewed
  • Figure 5 Primary Research Techniques
  • Figure 6 Market Size Estimation
  • Figure 7 Key Opportunities
  • Figure 8 Scope of Real-World Evidence Solutions Market
  • Figure 9 Real-World Evidence Solutions Market, by Component
  • Figure 10 Real-World Evidence Solutions Market, by Application
  • Figure 11 Real-World Evidence Solutions Market, by End User
  • Figure 12 Key Adopters
  • Figure 13 Market Dynamics
  • Figure 14 Percentage Distribution of Population Aged 65 Years & Above, by Region, 2015-2050
  • Figure 15 Increasing Number of People with Chronic Conditions
  • Figure 16 Key Findings on Drug Development
  • Figure 17 Global Real-World Evidence Solutions Market, By Component, 2019-2024 ($Million)
  • Figure 18 U.S.: Key Findings of EHR
  • Figure 19 Use of E-Prescription in U.S., 2017
  • Figure 20 Percentage of Specialists Using E-Prescriptions in the U.S., 2017
  • Figure 21 Real World Evidence Solutions Market, by Application, 2019-2024 ($Million)
  • Figure 22 Global Cancer Incidence and Mortality, 2018
  • Figure 23 Key Findings of Alzheimer's and other Dementias in the U.S.
  • Figure 24 Global RWE Solutions Market Size, by End User, 2019-2024 ($Million)
  • Figure 25 Pharmaceutical R&D Spending, 2010-2015
  • Figure 26 Global Real-World Evidence Solutions Market Size, by Region, 2019-2024 ($Million)
  • Figure 27 Percentage of Office-Based Physicians with Electronic Health Record System in U.S., 2010-2015
  • Figure 28 Annual Novel Drug Approvals by CDER, 2010 - 2017
  • Figure 29 Real-World Evidence Conferences Held in U.S., 2018
  • Figure 30 Key Findings of Cancer in Canada, 2017
  • Figure 31 Total Project Breakdown by Therapeutic Area, 2017-18
  • Figure 32 Pharmaceutical Industry R&D Expenditure in European Countries, 2014
  • Figure 33 Pharmaceutical R&D Expenditure in Italy
  • Figure 34 Pharmaceutical R&D in Spain, 2015-16
  • Figure 35 Number of People >65 Years of Age in Japan, 2000-2050
  • Figure 36 Investigator Initiated Clinical Trials in Japan
  • Figure 37 Key Growth Strategies Adopted by Leading Players During January 2015-January 2019
  • Figure 38 Real-World Evidence Solutions Market: Competitive Benchmarking
  • Figure 39 Anthem, Inc.: Financial Overview (2015-2017)
  • Figure 40 Clinigen Group Plc: Financial Overview (2016-2018)
  • Figure 41 Cognizant Technology Solutions Corporation: Financial Overview (2015-2017)
  • Figure 42 IBM Corporation: Financial Overview (2015-2017)
  • Figure 43 ICON Public Limited Company: Financial Overview (2015-2017)
  • Figure 44 IQVIA: Financial Overview (2015-2017)
  • Figure 45 UnitedHealth Group: Financial Overview (2015-2017)
  • Figure 46 Oracle Corporation: Financial Overview (2015-2017)
  • Figure 47 PAREXEL International Corporation: Financial Overview (2015-2017)
  • Figure 48 PerkinElmer, Inc.: Financial Overview (2015-2017)
  • Figure 49 Syneos Health Inc.: Financial Overview (2015-2017)
目次

Real World Evidence (RWE) Market by Component (RWD, EMR, Claim, Patient Registry, Pharmacy, Service), Application (Oncology, CVD, Neuro, Infection, Regulatory), End User (Pharma, Biotech, Medical Devices, Payers, Healthcare) - Global Forecast to 2024

The real-world evidence (RWE) solutions market is expected to grow at a CAGR of 15.0% from 2019 to reach $1.64 billion by 2024. The researchers believe that explosive growth will be driven by a variety of factors. These include rising geriatric population and burden of chronic diseases, shift towards value-based care, and growing focus on personalized health care. In addition, factors such as increasing R&D expenditure in life sciences industry, delays in drug development along with subsequent increase in development costs and expanding use of RWE for regulatory decision making are also supporting the growth of the market. However, uneven quality of real-world data sources and lack of standards are expected to hinder the growth of real-world evidence (RWE) solutions market to some extent.

Significant potential in emerging markets, rising focus on end-to-end RWE services, and emerging roles of wearable devices and AI in RWE represent high-growth opportunities for players operating in real-world evidence solutions market.

Real-world data sets are widely adopted by end-users for RWE for various applications such as drug development & approvals, market access & reimbursement/coverage decisions, clinical decision-making, and medical device development & approvals, among others. The report states that drug development & approvals currently accounts for the largest share of the total market owing to increasing need for additional insights on epidemiology, compliance, adherence and costs in a realistic environment; increasing demand of RWD and RWE to accelerate drug discovery and development; growing investment by biopharmaceutical companies in R&D; and growing inclination of regulatory bodies towards RWE.

Pharmaceutical, biotechnology & medical device companies were the leading adopters of real-world evidence solutions in 2018 and are also expected to register fastest growth during the forecast period. This is attributed to the increasing importance of RWE studies in drug development and approvals, growing focus to avoid costly drug recalls, increasing need to assess drug performance in real-world settings, and growing emphasis on drug safety and post-market surveillance.

An in-depth analysis of geographic scenario of the industry provides detailed qualitative and quantitative insights about the four major geographies (North America, Europe, Asia-Pacific, and Rest of the World) along with the coverage of major countries in each region. North America commanded the largest share of the real-world evidence solutions market in 2018, followed by Europe and Asia-Pacific. The largest share and fastest growth of this region is mainly attributed to significant availability of real-world data sets, growing focus on value-based care, rising R&D expenditure by the biopharma companies, greater emphasis on early drug/device development and approvals, presence of major RWE players in the region, stringent regulations for drug approvals, and supporting government policies (implementation of 21st Century Cures Act (December 2016) and FDA's new 2019 strategic Framework for RWE (December 2018) in the U.S).

Some of the major players operating in the RWE solutions market are Anthem, Inc., Clinigen Group plc, Cognizant, IBM Corporation, ICON plc, IQVIA, Optum, Inc., OracleCorporation, PAREXEL International Corporation, PerkinElmer Inc., Pharmaceutical Product Development, LLC., SAS Institute Inc., and Syneos Health, among several others.

Scope of the Report:

Real-World Evidence Solutions Market, by Component

  • Data Sets
  • Disparate data sets
    • EMR/EHR/Clinical data
    • Pharmacy data
    • Product/disease registries
    • Claims & billing data
    • Other data
  • Integrated data sets
  • Services

Real-World Evidence Solutions Market, by Application

  • Drug development & approvals
  • Oncology
  • Cardiovascular diseases
  • Neurology
  • Immunology
  • Other Therapeutic Areas
  • Market access &reimbursement/coverage decisions
  • Clinical decision-making
  • Medical device development & approvals
  • Other applications

Real-World Evidence Solutions Market, by End User

  • Pharmaceutical, biotechnology&medical device companies
  • Healthcare payers
  • Healthcare providers
  • Other End users

Real-World Evidence Solutions Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • China
    • Japan
    • Rest of APAC (RoAPAC)
  • Rest of the World

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Currency and Limitation
    • 1.2.1. Currency
    • 1.2.2. Limitations
  • 1.3. Key Stakeholders

2. Research Methodology

  • 2.1. Research Process
    • 2.1.1. Secondary Research
    • 2.1.2. Primary Research

3. Executive Summary

4. Market Insights

  • 4.1. Introduction
  • 4.2. Drivers
    • 4.2.1. Rising Geriatric Population and Burden of Chronic Diseases
    • 4.2.2. Shift Towards Value-Based Care
    • 4.2.3. Growing Focus on Personalized Health Care
    • 4.2.4. Delays in Drug Development and the Subsequent increase in Development Costs
    • 4.2.5. Expanding Use of RWE for Regulatory Decision Making
  • 4.3. Restraint
    • 4.3.1. Uneven Data Quality & Reluctance to Rely on Real-World Studies
  • 4.4. Opportunities
    • 4.4.1. Growth Opportunities in Emerging Markets
    • 4.4.2. Rising Focus on End-To-End RWE Services
    • 4.4.3. Emerging Roles of Wearable Devices and AI in RWE
  • 4.5. Challenge
    • 4.5.1. Lack of Standardized Methodologies to Develop RWE

5. Real-World Evidence Solutions Market, By Component

  • 5.1. Introduction
  • 5.2. Data Sets
    • 5.2.1. Disparate Data Sets
      • 5.2.1.1. EMR/EHR/Clinical Data
      • 5.2.1.2. Claims & Billing Data
      • 5.2.1.3. Pharmacy Data
      • 5.2.1.4. Product/Disease Registries Data
      • 5.2.1.5. Other Data
    • 5.2.2. Integrated Data Sets
  • 5.3. Consulting/ Services

6. Real-World Evidence Solutions Market, By Application

  • 6.1. Introduction
  • 6.2. Drug Development & Approvals, by Therapeutic Area
    • 6.2.1. Oncology
    • 6.2.2. Cardiovascular Diseases
    • 6.2.3. Neurology
    • 6.2.4. Immunology
    • 6.2.5. Other Therapeutic Areas
  • 6.3. Market Access & Reimbursement/Coverage Decisions
  • 6.4. Clinical Decision Making
  • 6.5. Medical Device Development & Approvals
  • 6.6. Others

7. Real-World Evidence Solutions Market, By End User

  • 7.1. Introduction
  • 7.2. Pharmaceutical, Biotechnology & Medical Device Companies
  • 7.3. Healthcare Payers
  • 7.4. Healthcare Providers
  • 7.5. Other End Users

8. Real-World Evidence Solutions Market, By Geography

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. U.S.
    • 8.2.2. Canada
  • 8.3. Europe
    • 8.3.1. U.K.
    • 8.3.2. Germany
    • 8.3.3. France
    • 8.3.4. Italy
    • 8.3.5. Spain
    • 8.3.6. Roe
  • 8.4. Asia-Pacific (APAC)
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. RoAPAC
  • 8.5. Rest of the World (RoW)

9. Competitive Landscape

  • 9.1. Key Growth Strategies
  • 9.2. Competitive Benchmarking

10. Company Profiles

  • 10.1. Anthem, Inc.
    • 10.1.1. Business Overview
    • 10.1.2. Financial Overview
    • 10.1.3. Product Portfolio
    • 10.1.4. Strategic Developments
  • 10.2. Clinigen Group plc
    • 10.2.1. Business Overview
    • 10.2.2. Financial Overview
    • 10.2.3. Product Portfolio
    • 10.2.4. Strategic Developments
  • 10.3. Cognizant Technology Solutions (CTS) Corporation
    • 10.3.1. Business Overview
    • 10.3.2. Financial Overview
    • 10.3.3. Product Portfolio
    • 10.3.4. Strategic Developments
  • 10.4. IBM Corporation
    • 10.4.1. Business Overview
    • 10.4.2. Financial Overview
    • 10.4.3. Product Portfolio
    • 10.4.4. Strategic Developments
  • 10.5. ICON plc
    • 10.5.1. Business Overview
    • 10.5.2. Financial Overview
    • 10.5.3. Product Portfolio
    • 10.5.4. Strategic Developments
  • 10.6. IQVIA
    • 10.6.1. Business Overview
    • 10.6.2. Financial Overview
    • 10.6.3. Product Portfolio
    • 10.6.4. Strategic Developments
  • 10.7. Optum (A Subsidiary of United Health Group, Inc.)
    • 10.7.1. Business Overview
    • 10.7.2. Financial Overview
    • 10.7.3. Product Portfolio
    • 10.7.4. Strategic Developments
  • 10.8. Oracle Corporation
    • 10.8.1. Business Overview
    • 10.8.2. Financial Overview
    • 10.8.3. Product Portfolio
    • 10.8.4. Strategic Developments
  • 10.9. PAREXEL International Corporation
    • 10.9.1. Business Overview
    • 10.9.2. Financial Overview
    • 10.9.3. Product Portfolio
    • 10.9.4. Strategic Developments
  • 10.10. PerkinElmer Inc.
    • 10.10.1. Business Overview
    • 10.10.2. Financial Overview
    • 10.10.3. Product Portfolio
    • 10.10.4. Strategic Developments
  • 10.11. Pharmaceutical Product Development, LLC
    • 10.11.1. Business Overview
    • 10.11.2. Financial Overview
    • 10.11.3. Product Portfolio
    • 10.11.4. Strategic Developments
  • 10.12. SAS Institute Inc.
    • 10.12.1. Business Overview
    • 10.12.2. Financial Overview
    • 10.12.3. Product Portfolio
    • 10.12.4. Strategic Developments
  • 10.13. Syneos Health, Inc.
    • 10.13.1. Business Overview
    • 10.13.2. Financial Overview
    • 10.13.3. Product Portfolio
    • 10.13.4. Strategic Developments

11. Appendix

  • 11.1. Questionnaire
  • 11.2. Available Customization
Back to Top